Morin is a natural occurring flavonoid in many dietary plants and has a wide range of beneficial effects on metabolism; however, the mechanism underlying its action remains elusive.
Introduction
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease with a prevalence of about 25-45% in the normal adult population (Rinella, 2015) , which increases to 70-80% in patients with obesity and diabetes (Pendino et al., 2005; Chalasani et al., 2012) . NAFLD encompasses a range of histological spectrum from simple steatosis to nonalcoholic steatohepatitis, which can progress to fibrosis and cirrhosis. Currently, there is no approved therapy for NAFLD. Hence, there is an urgent need to develop novel treatments for this complex medical condition.
Liver X receptors (LXRs), which comprise LXRα and LXRβ, are sterol-regulated nuclear receptor transcription factors involved in the regulation of lipids, fatty acid and glucose homeostasis. LXRs are pharmacological targets for hypercholesterolaemia and atherosclerosis (Viennois et al., 2011; Hong and Tontonoz, 2014) . However, LXR agonists increase triglycerides (TGs) and induce severe hepatic steatosis and hypertriglyceridaemia in mice (Schultz et al., 2000; Grefhorst et al., 2002) . LXR knockout mice are resistant to obesity and lipid accumulation in liver when fed a high-fat (HF) diet (Kalaany et al., 2005) . In NAFLD patients, LXR expression is directly correlated with the degree of hepatic fat accumulation, inflammation and fibrosis (Ahn et al., 2014) . Thus, it is likely that LXR antagonism can be used as a treatment for fatty liver disease.
Morin (morin hydrate), 2 0 ,3,4 0 5,7-pentahydroxyflavone, is a flavonoid present in mulberries, Tartary buckwheat, jackfruit, green tea, osage oranges and several other plants. Morin has been considered as a promising natural drug (Caselli et al., 2016; Sinha et al., 2016) because of its wide spectrum of biological effects, which include antioxidant (Subash and Subramanian, 2009; Rizvi et al., 2015) , anti-inflammatory (Wang et al., 2013; Dhanasekar and Rasool, 2016) , anticancer (Park et al., 2014) , anti-ageing and cardiovascular protective. These may have beneficial actions in cancer (Nandhakumar et al., 2012) , liver fibrosis (Heeba and Mahmoud, 2014; MadanKumar et al., 2014) , Alzheimer's disease (Noor et al., 2012 ), Parkson's disease (Lee et al., 2016) , and many other chronic diseases. Recently, morin was shown to reduce blood pressure (Prahalathan et al., 2012) , improve endothelial dysfunction in diabetic animals (Taguchi et al., 2016) , ameliorate blood glucose, serum lipid and liver TG levels (Vanitha et al., 2014; Naowaboot et al., 2016) , mimic the effects of insulin (Paoli et al., 2013) and inhibit fatty acid synthase (FAS) (Tian, 2006) . However, the underlying mechanisms of morin's effects have not been elucidated In a screening of LXR ligands from natural products with a reporter assay, we found that morin inhibited both the transactivities of both LXRα and LXRβ. In the present study, we demonstrated that morin is an LXR antagonist and the LXRs play an important role in fatty liver development in diet-induced obese (DIO) mice.
Methods
Cell culture and treatment 3T3-L1 (from ATCC, Manassas, Virginia, USA) adipocyte differentiation experiments were performed as previously described (Huang et al., 2006) . Briefly, cells were grown to full confluence for 2 days, and then differentiation medium containing 10 μg·mL À1 insulin, 0.5 μM dexamethasone and 0.8 mM IBMX was added to the culture. After 2 days, the medium was changed to DMEM for differentiation (day 0) with 92% O 2 and 8% CO 2 . Morin, 5, 10 
Transient transfection and luciferase reporter assays
The Dual-Luciferase Reporter Assay System (Promega, Madison, Wisconsin, USA) was performed as previously described (Zhang et al., 2014) . For the nuclear receptor transcription activity assay, the expression plasmids for the farnesoid X receptor (phFXR), phRXR and FXR response reporter (EcRE-LUC), pCMXGalhPPARα/γ, LXRα/β, and pregnane X receptor (PXR)-ligand binding domain (LBD) and the Gal4 reporter vector MH100 × 4-TK-Luc were co-transfected with 0.1 μg of pREP7 (Renilla luciferase) reporter for normalizing transfection efficiencies to HEK293T cells (ATCC) for 24 h. Then the FXR, PPARα, PPARγ, LXRs and PXR agonists (GW4064, WY14643, rosiglitazone, GW3965 and rifampicin respectively, 10 μM) and morin (10, 25 and 50 μM) or (50 μM) were added to media, and the cells were incubated for another 24 h to determine luciferase activities. All transfection experiments were repeated at least three times independently.
Animal studies
All animal protocols used in this study were approved by Shanghai University of Traditional Chinese Medicine (approval number: 12003). Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . Female C57BL/6 mice purchased from the SLAC Laboratory (Shanghai, China) were housed and bred in polycarbonate cages and kept at a controlled temperature of 22-23°C and a humidity of 50-60% with a 12 h light/12 h dark cycle. All the animals were adapted to the standard housing conditions for 1 week before experiments. For the preventive experiment, 21 of 9-week-old female mice were randomly divided into three groups: chow group (10% of calories derived from fat, n = 7), HF group (60% of calories derived from fat, n = 7) and morin group (HF diet supplemented with morin powder, at a dose of 100 mg . 100 g -1 diet, n = 7). Mice were treated for 8 weeks. Body weight and food intake were measured every 2 days using an electronic scale. For the therapeutic treatment, obesity was induced in 12-week-old female mice with a HF diet for 3 months. Then the mice were randomly divided into groups (n = 7 for each group) and received the same treatment as the preventive experiment for 4 weeks. For the effect of morin to be assessed on LXRβ À/À mouse, were fed a HF diet or HF diet plus morin at 100 mg . 100 g -1 for 12 weeks. Body weight and food intake were recorded and analysed as described above. Glucose levels were examined at 0, 15, 30, 60, 90 and 120 min after the injection.
Glucose and insulin tolerance tests

Rectal temperature measurement
At the end of the treatment period, the mice rectal temperature was measured using a rectal probe connected to a digital thermometer (Physitemp, Clifton, NJ, USA).
Serum chemistry analysis
Mice were anaesthetized with 20% urethane (Sigma), and cardiac blood was taken. Serum was separated by centrifuged at 800 g for 10 min. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), TG, total cholesterol (TC), HDL cholesterol (HDL-c), and LDL cholesterol (LDL-c) were measured using a Hitachi 7020 Automatic Analyser (Hitachi, Ltd., Tokyo, Japan).
Western blotting
Whole-tissue lysates from livers of diet-induced obese (DIO) mice were separated by 10% SDS-PAGE and transferred to nitrocellulose membranes. The membranes were probed with antibodies specific for mouse β-actin (#8H10D10; Cell Signaling Technology, Danvers, MA, USA), p-Akt (#9271; Cell Signaling Technology) and Akt (#9272; Cell Signaling Technology) with 1:1000 dilution in 5% BSA at 4°C overnight followed by IRDyeTM-labelled secondary antibodies (1:10 000) for 1 h at room temperature. Immunoreactive proteins were visualized using LI-COR Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, Nebraska, USA), according to the manufacturer's instructions. The relative pAkt protein levels were normalized to Akt. Experiments were repeated at least three times independently.
Analysis of liver and faecal lipid content
Liver and faecal lipid content was measured as described previously (Zhang et al., 2014) . Briefly, the liver tissue or faeces were homogenized and extracted with equal volumes of chloroform-methanol. The chloroform phase was removed to a new tube and dried and was then resuspended in isopropyl alcohol. The quantities of TC and TGs (KINGHA WK, China) in liver and faeces were then assayed using kits by following the manufacturer's protocols.
Liver TG release
Morin (10 mg·kg À1 body weight) or saline were injected i.p. to DIO mice. After 60 min of injection, 600 mg·kg À1 of tyloxapol, a lipoprotein lipase (LPL) inhibitor that blocks the degradation of TGs in plasma, was administered at the 0 min time point. Blood samples were collected at 0, 60, 120 and 180 min after the i.p. injection of tyloxapol to determine plasma TG levels.
Histochemistry
Liver tissues were fixed in formalin, and paraffin-embedded or frozen sections were prepared at 5 μm thickness. Sections were stained with haematoxylin and eosin or Oil Red O according to a standard procedure.
Scanning electron microscopy
Abdominal adipose tissues were fixed in 10% neutral formalin and then embedded in 1% osmium tetraoxide. A Philip XL-30 scanning electron microscope was used to observe the structure of fat tissue according to previously described methods (Zhang et al., 2014) .
ELISA
Serum insulin, leptin and adiponectin levels were measured using ELISA kits, from ALPCO Diagnostics (Salem, NH, USA), R&D Systems (Oxon, UK) and AdipoGen (Seoul, Korea), respectively, by following the manufacturer's instructions.
Determination of intracellular TG levels
TG contents in HepG2 cells (from ATCC) were measured as previously described (Gu et al., 2016) . HepG2 cells were grown in DMEM containing 5.5 mmol·L À1 D-glucose. Cells were seeded on a 12-well plate, and the cell growth was quenched overnight in serum-free DMEM, containing normal glucose levels (30 mmol·L À1 D-glucose), when cells had grown to 70% confluence. Then the cells were treated with 20 μM morin or vehicle (0.1% DMSO) for 24 h. The cells were homogenized in lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton) and mixed with an equal volume of chloroform, followed by centrifugation at 16 000× g for 15 min at 4°C. The chloroform layer was separated, dried and resuspended in 50 μL of isopropyl alcohol to measure the TG contents. Protein concentrations were measured using a Bio-Rad Protein Assay Kit (Bio-rad, Berkeley, California, USA 
Quantitative PCR
Total RNA from tissues or cells was isolated using the TRIzol method (Invitrogen, Carlsbad, CA). The integrity and purity of RNA were monitored according to the ratio of A260/280. The total RNA was incubated with DNase (1 U·μg À1 RNA) and quantified using the Nanodrop 2000 system. The first-strand cDNA was synthesized with a cDNA synthesis kit (Fermentas, Madison, WI, USA) and 1 μg RNA. cDNA (10 ng) was subjected to quantitative real-time PCR using SYBR green PCR Mastermix. The data were analysed on an ABI StepOnePlus real-time PCR system (Applied Biosystems, Carlsbad, California, USA) with β-actin as control. Sequences for primers are listed in Supporting Information Tables S1 and S2 . Experiments were repeated at least three times independently.
Nuclear receptor coactivator assays
The time-resolved FRET (TR-FRET) LXRα/β coactivator assay (Invitrogen) was used to determine the ability of morin to compete with the LXR agonist T0901317 for the LBD of LXRα/β, according to the manufacturer's protocol.
Statistical analysis
All values are expressed as means ± SEM and were analysed using the statistical software package for social science (SPSS, version 15.0). Student's paired or unpaired two-tailed t-tests were used to detect differences between the mean values of the treatment group and control, and ANOVA was used for assessing the difference among more than two groups. Differences with P values <0.05 were considered to be statistically significant. The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) .
Compounds
Morin with 95% purity was obtained from Yuanye Biol Comp (Shanghai, China 
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015a,b,c) .
Results
Morin is a dual LXRα/β antagonist
Luciferase transcriptional activity assays were performed with the LBD of LXRα and LXRβ (Mitro et al., 2007) to analyse the effects of morin ( Figure 1A ) on the LXR transcription activity. We found that morin inhibited both LXRα and LXRβ
Figure 1 transactivities induced by their agonist GW3965 in a dosedependent manner ( Figure 1B , C), with higher efficacy on the LXRβ transactivity than on that of the LXRα. Next, we analysed the effects of morin on PPARα, PPARγ, FXR and PXR transactivity using the reporter assay. The results showed that morin did not change the transactivity of these nuclear receptors induced by their agonists ( Figure 1D -G), suggesting that morin may be a specific antagonist of LXRα/β. Subsequently, the TR-FRET coactivator assay was used to further confirm the direct binding of morin to LXRs. The results showed that the dual LXRα/β agonist T0901317 bound to both LXRα-and LXRβ-LBD ( Figure 1H ). Morin significantly inhibited the binding of T0901317 to both LXRα and LXRβ with an IC 50 value of 4.08 and 5.17 μM (Ki 1.464 and 1.857 μM) respectively ( Figure 1I ). These results suggest that morin is a specific antagonist of LXRα/β.
Morin blocks body weight gain induced by a high-fat diet
Since deficiency of LXRs results in lower body weight, we examined the effects of morin on body weight gain in the HF diet-fed mice. HF diet feeding resulted in an increase in body weight in control mice by approximately 11 g within 8 weeks.
However, morin supplementation blocked the body weight gain of obese mice by approximately 20% compared with the HF diet-fed control ( Figure 2A ) (P < 0.05). The decrease in body weight was not due to decreased food intake since food intake was not altered ( Figure 2B ). Using a scanning electron microscope, we found that the size of white adipocytes was increased in HF diet-fed mice. However, morin treatment reduced adipocyte size ( Figure 2C ) (P < 0.05). These results indicate that morin protects mice from HF diet-induced increase in fat mass. LXR is a regulator of lipid and glucose haemostasis. So we assayed fasting blood glucose, GTT, ITT and serum lipid levels. As shown in Figure 2D , the glucose levels in HF diet-fed mice were increased compared with those in the chow-fed mice. Morin treatment resulted in a decrease in the glucose levels at the 90 and 120 min time points following glucose injection (P < 0.05), suggesting that morin improves glucose tolerance of HF diet-fed C57BL/6 mice. For ITT, morin decreased blood glucose level only at 90 min ( Figure 2E ) (P < 0.05). Serum lipid tests showed that morin treatment led to a decrease in TG, TC and HDL-c levels in the mice (P < 0.05), but LDL-c levels remained unchanged ( Figure 2F ).
Morin lowers serum TG contents in DIO mice
Next, we examined whether morin treatment could reverse metabolic disorders in DIO mice. Body weights were increased in mice fed a HF diet ( Figure 3A ) (P < 0.05). Morin did not lower the body weight ( Figure 3A) . The serum TG, TC, LDL-c, HDL-c and free fatty acid (FFA) levels were also and HDL-c levels. The data were shown as mean ± SEM. n = 7 for all groups. * P < 0.05 compared with chow-or HF-group of mice. NS, no significance.
elevated in DIO mice compared with the chow-fed mice. Morin treatment markedly reduced the serum TG (P < 0.05), but not FFA, TC, LDL-c and HDL-c levels ( Figure 3B , C). The amount of food consumed, faeces, TG contents and body temperature of the mice was unchanged by morin ( Figure 3D-F) , suggesting that morin reduces serum TG levels via the synthesis of TGs rather than inhibition of the absorption from food. Mice fed a HF diet had a significantly impaired glucose tolerance compared with the chow diet-fed group. The morin-treated HF-fed mice showed improved glucose tolerance, suggesting that morin prevents the effects of the HF diet on glucose tolerance ( Figure 3G ). We then performed ITTs. Similarly, blood glucose levels were reduced at 15, 30, 60, 90 and 120 min time points after i.p. injection of insulin ( Figure 3H ).
Morin decreases lipid accumulation and reverses hepatic steatosis in the liver of DIO mice
To examine the effects of morin on hepatic steatosis, we tested the fat content and lipid profiles in the liver of the DIO mice. Haematoxylin and eosin staining and Oil Red O staining showed that the liver sections of mice fed a normal-fat diet had normal morphology, whereas those from HF-fed mice exhibited steatotic hepatocytes. Morin treatment reduced the lipid accumulation and improved the morphology of the liver of the HF-fed mice when compared with the chow-diet control group ( Figure 4A ). The ratios of liver/body weight in chow-fed mice were significantly higher than that in HF-fed mice, while there was no obvious change in the ratio of liver/body weight between the HF-fed and morin-treated HF-fed group of mice ( Figure 4B) . Furthermore, the liver TG and TC levels were higher in the DIO mice than in chow-fed mice ( Figure 4C , D) (P < 0.05). Morin treatment decreased liver TG levels by approximately 50% in the DIO mice ( Figure 4C ), while the TC content was not changed in the morin-treated DIO mice ( Figure 4D ). Then we analysed whether morin could reverse the liver damage induced by the HF diet. As shown in Figure 4E , F, serum alanine ALT and AST levels were increased in DIO mice (P < 0.05). Morin treatment decreased serum ALT and AST concentrations ( Figure 4E , F) (P < 0.05). Taken together, these results suggest that morin reverses liver lipid accumulation and hepatic steatosis and reduces liver damage in the DIO mice. for all groups. *P < 0.05 compared with chow or HF group mice. NS, no significance.
Morin improves insulin sensitivity in DIO mice
Morin treatment decreased insulin, but not leptin, levels in DIO mice ( Figure 5A , B), indicating that morin may alleviate insulin resistance in these mice. The level of adiponectin was notably decreased in DIO mice, and morin elevated these levels ( Figure 5C ). The level of intracellular phosphorylation of Akt protein reflects the activation of insulin signalling (Manning and Cantley, 2007) . Interestingly, chow-fed mice showed a high p-Akt level in liver tissue, and the HF diet decreased these p-Akt levels, whereas morin treatment increased p-Akt levels in the DIO mouse liver ( Figure 5D ). The quantitative data for p-Akt levels are shown in Figure 5E . Taken together, the data suggest that morin ameliorates metabolic disorders in DIO mice.
Morin inhibits lipogenesis in 3T3-L1 adipocytes and HepG2 cells via the suppression of LXR signalling
Next, we analysed whether morin inhibits lipogenesis or enhances the TG release from the liver. Plasma TG contents were not changed in DIO mice after 60, 120 and 180 min injection of tyloxapol, indicating that morin does not increase the TG secretion from the mouse liver ( Figure 6A ). To test whether morin inhibits lipogenesis, we used high-glucose medium to induce lipid synthesis in human hepatocellular carcinoma HepG2 cells. Morin treatment reduced the TG content of these cells ( Figure 6B ) and inhibited the expression of known LXR target genes, sterol regulatory element binding protein 1c (SREBP-1c), ATP-binding cassette, sub-family A, member 1 (ABCA1) and ATP-binding cassette, subfamily G, member 1 (ABCG1), as well as downstream genes of SREBP-1c including FAS and acetyl-CoA carboxylase (ACC) in the hepatic cell ( Figure 6C ). LXR activation enhances adipogenesis (Juvet et al., 2003; Laurencikiene and Ryden, 2012) , while inhibition of LXR suppresses adipogenesis (Seo et al., 2004) . To analyse the effects of morin on adipogenesis, we used the 3T3-L1 adipocyte differentiation model to study the effects of morin on the lipogenesis. The results showed that morin inhibited the differentiation of 3T3-L1 adipocytes in a dose-dependent manner ( Figure 6D ). We found that morin significantly suppressed mRNA expression of LXR target genes SREBP-1c, ABCA1 and ABCG1 as well as downstream genes SREBP-1c, FAS and ACC ( Figure 6E ). Collectively, our data suggest that morin may alleviate fatty liver through the inhibition of LXR signallingmediated lipogenesis.
LXRs mediate the reverse cholesterol transport in macrophages, which may block the development of atherosclerosis (Tangirala et al., 2002) . Thus, we examined whether morin inhibits the expression of ABCA1 and ABCG1, which are associated with the reverse cholesterol transport in mouse Raw 264.7 macrophage cells. Our results showed that morin decreased the mRNA levels of ABCA1 and ABCG1 (Figure 6F ), indicating that morin also inhibits LXR activity in macrophages. 
Morin inhibits the mRNA expression of LXR target genes
To determine whether morin suppresses the downstream genes of LXRs, the mRNA levels of SREBP-1c, FAS, ABCG1, ABCA1, LPL, apolipoprotein E (ApoE) and cholesterol 7-α hydroxy-lase (CYP7A1) in the morin-treated DIO mouse liver were assayed (Figure 7) . The results show that morin significantly decreased the mRNA levels of SREBP-1c, ABCA1 and ApoE but did not change the expression of ABCG1, FAS, LPL and CYP7A1 (Figure 7) . We also examined the downstream genes of SREBP-1c and showed that SCD1 mRNA was inhibited in morin-treated mouse liver. These data indicate that morin inhibits LXR signalling in vivo.
Lack of effects of morin on LXRβ
Morin is more effective on LXRβ than LXRα transcriptional activity. We tested the effects of morin in LXRβ À/À mice. As expected, morin did not decrease the body weight, white adipocyte size, serum lipid levels, fasting blood glucose contents or GTT and ITT in the HF diet-fed LXRβ À/À mice ( Figure 8A -E). Morin seemed to reduce lipid accumulation in the liver of these mice ( Figure 8F) ; however, the TG concentration in the liver was unaffected by the morin treatment ( Figure 8G ). These data indicated that the effects of morin on metabolic disorders are attenuated in LXRβ À/À mice ( Figure 8A-G) , further demonstrating that morin is an LXR antagonist.
Discussion
In the present study, we provided strong evidence indicating that morin is a natural occurring dual LXRα/β antagonist. Firstly, the gene reporter assay showed that morin inhibited both LXRα and β transcription activities induced by GW3965. Secondly, the TR-FRET coactivator assay confirmed that morin competed with the LXR agonist T0901317 to bind with the LBD of LXRα and β with K i values of 1.464 and 1.857 μM respectively. Finally, morin was shown to inhibit the expression of LXR downstream genes in the mouse liver, 3T3-L1 adipocytes and human hepatic carcinoma HepG2 cells. Thus, we identified morel as a novel antagonist of LXRs. LXRs are key regulators of lipogenesis and glucose homeostasis (Hong and Tontonoz, 2014) . LXR agonists are cholesterol-lowering agents. However, these agonists have been found to induce fatty liver and hypertriglyceridaemia in animals (Grefhorst et al., 2002; Cha and Repa, 2007; Gao et al., 2013) . LXR-deficient mice exhibited resistance to the development of fatty liver when fed a HF diet. Thus, suppressing LXR activity may be a therapeutic choice for fatty liver diseases. Several synthetic and natural LXR antagonists have been assessed for their ability to reduce the TG levels in liver and so prevent the effects of a fatty liver (Hoang et al., 2012; Huang, 2014) .
Previous studies showed that morin can modulate lipid and glucose metabolism. However, the underlying mechanism remains unclear. In the present study, we demonstrated that morin prevents mice fed a HF diet from gaining weight, reduced their fasting blood glucose, improved glucose and insulin tolerance and increased phosphorylation of Akt, indicating that morin improves insulin signalling. In a previous study it was suggested that a reduction in LXR activity could be beneficial to insulin resistance. Deletion of both LXRα and LXRβ in the ob/ob mouse have been shown to improve insulin sensitivity and lipid accumulation in liver (Beaven et al., 2013) . Thus, an LXR antagonist might ameliorate fatty liver and insulin resistance in metabolic syndrome. Our results indicate that morin alleviates metabolic disorders through an LXR-dependent increase in insulin sensitivity. LXR agonists are known to lower cholesterol levels. In principle, the inhibition of LXRs should result in an increase in TC levels. However, morin failed to increase TC contents in our control (chow-fed) mice, even though the downstream genes of LXR were suppressed. In contrast, morin prevented the increase in serum TC-LDL-c levels in the HF diet-fed mice. Similar results have also been reported for several other LXR antagonists (Kase et al., 2007; Fan et al., 2012) . These data suggest that morin does not increase TC levels in mice.
LXR agonists promote TG synthesis in the liver and cause enlarged fatty liver in mice (Cha and Repa, 2007; Gao et al., 2013) . Moreover, LXRα-and LXRβ-deficient mice have reduced hepatic steatosis and improved insulin sensitivity. We found that morin indeed alleviated the lipid accumulation, improved morphology in hepatic tissues, lowered TG contents and ameliorated liver damage, which is in agreement with observations with other LXR antagonist and a liverspecific reverse agonist (Huang, 2014) . LXRs may directly modulate the hepatic lipogenesis or affect the absorption of TGs in the intestine (Briand et al., 2016) . Since morin did not change the TG content of faeces ( Figure 3E ), we analysed the inhibitory effects of morin on lipogenesis in 3T3-L1 adipocytes and hepatic HepG2 cells. As expected, the lipogenesis in both cells was inhibited. Hence, these data suggest that morin is a lipogenesis inhibitor in liver.
As a lipid sensor, LXRs regulate the expression of genes that modulate the metabolism of lipids in liver. Treatment with the LXR agonist T0901317 results in severe hypertriglyceridemia and hepatic TG accumulation (Chisholm et al., 2003) , whereas T0901317 eliminated the increase in plasma TG in liver-specific LXRα knockout mice, suggesting that the activation of liver LXR may mediate the increased accumulation of TGs . A liver-selective LXRα/β inverse agonist, SR9238, has been shown to suppress lipogenesis and hepatic lipid accumulation in diet-induced obese mice. Thus, liver-selective LXR antagonism may hold utility in the treatment of liver diseases (Griffett et al., 2013) . SREBP-1c, the master regulator of hepatic lipogenesis through the downstream genes FAS, ACC and SCD-1, is regulated by LXRs . LXR stimulates lipogenesis through the induction of SREBP-1c, ACC, SCD-1 and FAS expression (Chisholm et al., 2003) . The overexpression of SREBP-1c results in a fatty liver due to an increased lipogenesis, whereas SREBP-1c deficiency blocks the development of a fatty liver in ob/ob mice (Shimomura et al., 1999; Yahagi et al., 2002) . To understand the mechanisms by which morin alleviated the metabolic disorders induced by the HF diet, we analysed the expression of LXR downstream genes involved in lipid metabolism in liver tissues. We found that morin decreased the expression of SREBP-1c in the liver of mice, 3T3-L1 adipocytes and HepG2 cells and further affected the levels of its target genes SCD1, FAS and ACC. Thus, morin may modulate lipid metabolismrelated gene expression by suppressing the LXR mediated transcription of SREBP-1c.
The functions of LXRα and LXRβ are overlapping but not identical. LXRα is important for the maintenance of resistance to dietary cholesterol, and LXRβ seems to be a regulator of glucose metabolism, energy utilization and body weight (Korach-Andre et al., 2010) . Intestinal-specific overexpression of LXRα in mice reduces intestinal cholesterol absorption (Lo Sasso et al., 2010); in contrast, selective activation of LXRβ increases cholesterol absorption and elevates serum levels of apoB-containing lipoproteins , suggesting the different effects of these two LXRs on the regulation of cholesterol. We tested the effects of morin on metabolic disorders in LXRβ À/À mice, because morin is more effective on the transcriptional activity of LXRβ than LXRα. Morin did not induce any significant improvements in the metabolic disorders in these LXRβ knockout mice, suggesting that morin exerts at least part of its therapeutic effects through LXRβ. LXR agonists may attenuate the formation of atherosclerotic plaque through an effect on the ABCA1-and ABCG1-mediated reverse cholesterol transport in macrophages . As an antagonist of LXR, morin inhibited the expression of ABCA1 and ABCG1 in macrophages, which may lead to the development of atherosclerosis. Therefore, the exact role of morin in atherosclerosis should be studied in the future.
In summary, we demonstrated that morin is a dual antagonist of LXRs. Morin blocked body weight gain in HF diet-fed mice, lowered the fasting blood glucose levels and improved glucose and insulin tolerance in DIO mice. In addition, morin reduced lipid accumulation in the liver through the inhibition of LXR-dependent lipogenesis. When taken together with previous findings, which showed morin has antioxidant and anti-inflammatory properties, our results indicate that the therapeutic effect of morin on NAFLD may be mediated through multiple mechanisms. Our data suggest that morin ameliorates metabolic disorders via the suppression of LXR signalling and morin may have potential as a therapy for fatty liver disease.
Figure 7
Morin inhibits the expression of LXR downstream genes. Real-time RT-PCR results of gene expression levels of SREBP-1c, ABCG1, LPL, ABCA1, ApoE, CYP7A1, SCD1 and FAS in the livers of morin-treated mice were compared with those of HF DIO mice. β-Actin was used as an internal control. Data are presented as means ± SEM of five mice per group. *P < 0.05 compared with the HF group of mice. 
